CARLSBAD, Calif., July 25, 2011 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, today commented on the United States Food and Drug Administration's (FDA) untitled letter dated June 23, 2011 that was sent to Parcell Laboratories, LLC regarding Alphatec Spine's PureGen Osteoprogenitor Cell Allograft product.
